PridCor Therapeutics

What PridCor Therapeutics does

PridCor Therapeutics is a privately held, clinical-stage biopharmaceutical company headquartered in Tuscaloosa, Alabama, developing combination antiviral therapies for Long COVID and infection-associated chronic illnesses (IACI) including ME/CFS, fibromyalgia, and IBS. Founded by Dr. William "Skip" Pridgen, MD — a board-certified surgeon with over 35 years of clinical experience who previously founded Virios Therapeutics (now NASDAQ-listed Dogwood Therapeutics) — the company pursues a dual-mechanism therapeutic strategy targeting viral reactivation and systemic inflammation simultaneously. Its core technology is a proprietary combination regimen of valacyclovir, celecoxib, and pulsed Paxlovid, with additional assets including PCT-1 Throat Spray for pharyngitis and oral mucositis and the PCT Trocar Lock, a 3D-printed surgical device.

The company's pipeline was substantially expanded in April 2026 through the acquisition of the IMC-1 (Phase 3-ready for fibromyalgia) and IMC-2 (Phase 2b-ready for Long COVID) portfolio from Dogwood Therapeutics in a deal capping total potential payments at $100 million. Clinical development is anchored by the SHIELD Study, a randomized, double-blind, placebo-controlled Phase 2 trial at the Icahn School of Medicine at Mount Sinai, with Dr. David Putrino serving as Principal Investigator. PridCor received FDA IND exemption for the SHIELD Study in January 2026 and published its combination antiviral case series results in Frontiers in Immunology, establishing peer-reviewed scientific credibility.

PridCor operates on a licensing and royalties revenue model but is currently pre-revenue, with no commercialized products and 1-10 employees. The company relies on strategic partnerships with academic medical institutions rather than internal infrastructure, and leverages scientific publications, patient testimonials, and federal health policy engagement for visibility. Its near-term revenue mechanics depend on future commercialization milestones, with Dogwood Therapeutics entitled to tiered royalties up to 15% on net sales and 9% of future capital raised by PridCor.

Name

PridCor Therapeutics

Legal name

PridCor Therapeutics LLC

Website

https://pridcor.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

PridCor Therapeutics is a privately held, clinical-stage biopharmaceutical company developing combination antiviral therapies for Long COVID, ME/CFS, fibromyalgia, and IBS, advancing the SHIELD Study at Mount Sinai with an acquired late-stage pipeline.

Ownership category

akta.pro rank

Headquarters

HQ city

Tuscaloosa

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Commercialization: As a clinical-stage biopharmaceutical company, PridCor generates revenue through the development and future commercialization of antiviral therapies targeting Long COVID and infection-associated chronic illnesses. The company holds a pipeline of combination antiviral candidates in various clinical stages.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

PridCor Therapeutics is a clinical-stage biopharmaceutical company developing combination antiviral therapies for Long COVID and infection-associated chronic illnesses (ME/CFS, fibromyalgia, IBS), with its lead candidate being the PridCor Protocol — a proprietary fixed-dose combination of valacyclovir, celecoxib, and a third element designed to suppress viral reactivation and reduce inflammation. The portfolio also includes acquired Phase 2b/3-ready assets (IMC-2 and IMC-1) and two proprietary medical devices (PCT-1 Throat Spray and PCT Trocar Lock).

Product overview

PridCor Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of antiviral therapies and medical devices for post-viral syndromes and chronic conditions. The core offering is The PridCor Protocol (Combo Regimen), a proprietary combination of valacyclovir, celecoxib, and a third element designed to suppress viral reactivation and reduce inflammation in Long COVID and related conditions. The pipeline includes acquired assets IMC-2 (Phase 2b-ready for Long COVID) and IMC-1 (Phase 3-ready for fibromyalgia). Additionally, the company offers two medical devices: PCT-1 Throat Spray for pharyngitis and oral mucositis treatment, and PCT Trocar Lock, a 3D-printed surgical device. The therapies are being advanced through the SHIELD Study at Mount Sinai.

Differentiator

Problem solved

Functional benefit

Products and services

• The PridCor Protocol (Combo Regimen) Proprietary combination antiviral therapy comprising valacyclovir, celecoxib, and a third element designed to suppress viral reactivation and reduce systemic inflammation — the two key biological drivers of Long COVID and related post-viral syndromes. Advancing through the SHIELD Study at Mount Sinai.
• IMC-2 Phase 2b-ready fixed-dose combination antiviral targeting the full spectrum of Long COVID symptoms and related chronic conditions including ME/CFS, fibromyalgia, and IBS.
• IMC-1 Phase 3-ready candidate for fibromyalgia, providing PridCor with a late-stage asset positioned for near-term clinical advancement and potential value inflection.
• PCT-1 Throat Spray Proprietary throat spray that uniquely adheres to the posterior pharynx, consistently delivering therapeutic medication even after repeated swallowing. Addresses pharyngitis and oral mucositis in cancer patients undergoing head and neck radiation therapy.
• PCT Trocar Lock Custom-designed, 3D-printed medical device that prevents trocar slippage during robotic, laparoscopic, and minimally invasive procedures, providing surgeons enhanced control, improved outcomes, and greater procedural efficiency.

Quantifiable outcome

• Fatigue improved significantly (p<0.0001) by Patient-Reported Global Impression of Change (PGIC) in Long COVID patients receiving combination antiviral regimen
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• Dogwood TherapeuticscoreStrategic or Co-development Partner · 23 April 2026PridCor Therapeutics entered into a global development and commercialization partnership with Dogwood Therapeutics for its anti-viral candidates IMC-1 and IMC-2, granting PridCor full responsibility for future development and commercialization. In exchange, Dogwood receives tiered royalties up to 15% on net sales, 9% of future capital raised by PRIDCor, and development and regulatory milestone payments, with total potential payments capped at $100 million. The deal allows Dogwood to shift focus to its pain treatment pipeline.
• Dr. David PutrinocoreStrategic or Co-development Partner · 6 January 2026Dr. David Putrino, Director of Rehabilitation Innovation and Nash Family Director at the Cohen Center for Recovery from Complex Chronic Illnesses at Mount Sinai, serves as Principal Investigator of the SHIELD Study and participated in a national Long COVID roundtable convened by HHS Secretary Robert F. Kennedy Jr., representing PridCor's research at the federal level.
• Dr. Amy Proal (PolyBio Research Foundation)coreStrategic or Co-development Partner · 6 January 2026Dr. Amy Proal, President and CEO of PolyBio Research Foundation, serves as Co-Investigator for the SHIELD Study, contributing scientific expertise in infection-associated chronic conditions and Long COVID research.
• Icahn School of Medicine at Mount SinaicoreStrategic or Co-development Partner · 6 January 2025PridCor is collaborating with the Icahn School of Medicine at Mount Sinai for the SHIELD Study, a randomized, double-blind, placebo-controlled Phase 2 clinical trial for Long COVID. Dr. David Putrino serves as Principal Investigator and Dr. Amy Proal as Co-Investigator. This collaboration provides academic clinical trial infrastructure and scientific leadership.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Gilead Sciences: Major antiviral franchise (remdesivir, Veklury, lenacapavir) with established antiviral clinical infrastructure. Relevant comparable as a potential large-pharma partner interested in Long COVID therapeutics.
• Vir Biotechnology: Clinical-stage immunology company with broad antiviral and Long COVID programs (e.g., sotrovimab). Comparable in therapeutic area and modality, though much larger and broader in scope than PridCor.
• Pfizer: Large pharma that developed Paxlovid (nirmatrelvir/ritonavir), the third component of PridCor's Combo Regimen. Broad antiviral franchise and Long COVID R&D interest make Pfizer a relevant comparable and potential acquirer/partner.

Emerging players

• PureTech Health: Clinical-stage biopharma with Long COVID therapeutic programs and a broader pipeline targeting immune-mediated chronic conditions. Overlaps in mechanism and indication focus with PridCor's antiviral-combination thesis.
• BioVie Inc. Small clinical-stage biopharma developing therapies for neurological and inflammatory conditions, including Long COVID programs. Smaller scale but operating in adjacent indications and trial design.
• AIM Immunotech: Clinical-stage biotech developing Ampligen for ME/CFS and Long COVID. Direct indication overlap with PridCor's IACI portfolio, particularly around viral-immune drivers of chronic fatigue syndromes.

Direct peers

• Dogwood Therapeutics: Formerly Virios Therapeutics, founded by the same Dr. Pridgen. Develops antiviral combination therapies for fibromyalgia and is the source of PridCor's IMC-1/IMC-2 portfolio via the 2026 partnership deal.
• Tonix Pharmaceuticals: Clinical-stage biopharma developing therapeutics for Long COVID, fibromyalgia, and ME/CFS. Direct competitor in the post-viral / infection-associated chronic illness space where PridCor is also developing treatments.
• Axcella Therapeutics: Clinical-stage biotech that has run Long COVID trials and is developing multi-target metabolic/endogenous modulator therapies for complex chronic conditions, overlapping with PridCor's IACI focus.

Others

• Recursion Pharmaceuticals: AI-driven drug discovery platform exploring treatments for complex chronic diseases including post-viral conditions. Different modality (AI-enabled small molecule discovery) but adjacent in the broader therapeutics-for-IACI narrative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Pridcor
• YouTubeyoutube.com/@PridCor
• Facebookfacebook.com/PridCor
• LinkedInlinkedin.com/company/pridcor

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PridCor Therapeutics